Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Epileptic Encephalopathy: later-stage trial registry
3 of 4 indexed Epileptic Encephalopathy trials are currently recruiting, with more weight in Phase 3-4.
Corpus placement: #4,115 of 28,707 conditions by registered trial count.
4 US clinical trials · 3 currently recruiting · #4,115 of 28,707 conditions by registered trial count
Epileptic Encephalopathy: 4 US clinical trials tracked, 3 recruiting.
Epileptic Encephalopathy is the subject of 4 registered US clinical trials on ClinicalTrials.gov, 3 of them currently open to new participants. 2 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is Zogenix, running 1 of these trials.
Enrollment posture brief
Registry condition epileptic-encephalopathy
OPEN 3 | RECR 75% | LATE 2 | EARLY 1 | RANK #4115 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Activity, Motor (75% recruiting · 8 trials)
Epileptic Encephalopathy lists 3 open slots (75% of 4 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Epileptic Encephalopathy on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Epileptic Encephalopathy is recruiting above its size-band peers.
3 of 4 indexed trials (75%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
4 total, page 1 of 1
Genetics of Epilepsy and Related Disorders
Boston Children's Hospital
NCT01858285
A Clinical Trial of Elsunersen in Pediatric SCN2A-DEE to Assess Efficacy and Safety
Praxis Precision Medicines
NCT07019922
A First-in-human Study of S230815 in Pediatric Participants With KCNT1-related Developmental and Epileptic Encephalopathy
Institut de Recherches Internationales Servier
NCT07227857
A Study to Investigate the Long-Term Safety of ZX008 (Fenfluramine Hydrochloride) Oral Solution in Children and Adults With Epileptic Encephalopathy Including Dravet Syndrome and Lennox-Gastaut Syndrome
Zogenix
NCT03936777
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 3 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Epileptic Encephalopathy records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Epileptic Encephalopathy trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Epileptic Encephalopathy page
4 registered trials, 3 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 3 Epileptic Encephalopathy trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Zogenix sponsors the most Epileptic Encephalopathy trials on record, review their full trial history before evaluating a specific study. See Zogenix's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Epileptic Encephalopathy condition card totals 4 registered trials; most-linked intervention ZX008 (Fenfluramine Hydrochloride); top US site state Massachusetts. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.